Zydus Cadila gets USFDA nod to Doxazosin for treating BP, enlarged prostate issues
Doxazosin is used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia, it added.
New Delhi: Gujarat based drugmaker, Zydus Cadila has received approval from the United States Food and Drug Administration (USFDA) to market Doxazosin tablets. The drug is used to treat high blood pressure and urinary retention associated with enlargement of the prostate gland.
The company "has received the final approval from the United States Food and Drug Administration (USFDA) to market Doxazosin tablets USP, 1 mg, 2 mg, 4 mg, and 8 mg", Zydus Cadila said in a statement.
The drug is used to treat high blood pressure(hypertension) by relaxing blood vessels so blood can flow more easily. It is also used to treat urinary retention associated with benign prostatic hyperplasia. It does not shrink the prostate, but it works by relaxing the muscles in the prostate and part of the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate frequently or urgently (including during the middle of the night).
The company has also received the tentative approval from the USFDA to market Lurasidone Hydrochloride Tablets in the strengths of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, Zydus Cadila said.
The drug is used in the treatment of schizophrenia, it added.
Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. People with schizophrenia may seem like they have lost touch with reality. Although schizophrenia is not as common as other mental disorders, the symptoms can be very disabling.
Both Doxazosin tablets and Lurasidone Hydrochloride tablets will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad, Zydus Cadila said.
The group now has more than 120 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs), it added.
Cadila Healthcare is an Indian pharmaceutical company headquartered at Ahmedabad in Gujarat state of western India. It is a manufacturer of generic drugs.
Also Read: Srinagar: Doctors to boycott Zydus, Macleods, Intas, Sun pharma for suspending Kashmiri employees
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd